Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Amgen
Amgen
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
Fierce Pharma
Thu, 08/24/23 - 11:38 am
Amgen
Horizon Therapeutics
M&A
FTC
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
Wed, 08/23/23 - 11:11 am
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Mon, 08/21/23 - 06:56 pm
Amgen
Lumakras
KRAS inhibitors
FDA
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
Wed, 08/16/23 - 10:16 am
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Wed, 08/9/23 - 11:55 am
Mirati Therapeutics
Pharma CEOs
David Meek
Amgen
KRAS inhibitors
Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
BioSpace
Fri, 08/4/23 - 12:30 pm
Amgen
oncology
colorectal cancer
small cell lung cancer
tarlatamab
Lumakras
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Fierce Pharma
Fri, 08/4/23 - 11:56 am
Amgen
AbbVie
biosimilars
Humira
Amgen's tarlatamab BiTEs at small cell lung cancer in brief readout
Fierce Biotech
Thu, 08/3/23 - 06:37 pm
Amgen
tarlatamab
small cell lung cancer
T-cells
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
Wed, 07/26/23 - 11:37 am
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis
Amgen’s lupus bets continue to flounder, even those on the Horizon
Fierce Biotech
Mon, 07/24/23 - 10:24 am
Horizon Therapeutics
Amgen
lupus
daxdilimab
clinical trials
FTC, Amgen Break Off Settlement Talks Over Horizon Deal
BioSpace
Thu, 07/20/23 - 10:07 am
Amgen
Horizon Therapeutics
M&A
FTC
Biopharma buyouts bounce back
EP Vantage
Wed, 07/5/23 - 10:17 am
M&A
Amgen
Astellas
Eli Lilly
GSK
Horizon Therapeutics
Merck
Novartis
Pfizer
Seagen
States Back FTC in Lawsuit Seeking to Block Amgen-Horizon Deal
BioSpace
Fri, 06/23/23 - 09:53 am
Amgen
Horizon Therapeutics
M&A
FTC
Amgen granted full FDA approval for blood cancer treatment
Biopharma Reporter
Thu, 06/22/23 - 10:10 am
Amgen
Blincyto
FDA
blood cancer
Full circle for Paul Burton as Moderna exec returns to Amgen, this time for expanded CMO role
Fierce Biotech
Wed, 06/14/23 - 06:33 pm
Amgen
Moderna Therapeutics
Paul Burton
chief medical officers
Medicare sets next tranche of drugs to face price hike penalties
BioPharma Dive
Sun, 06/11/23 - 11:02 pm
Medicare
Inflation Reduction Act
drug pricing
Amgen
Sanofi
Seagen
Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices
BioSpace
Wed, 06/7/23 - 11:22 am
biosimilars
biologics
drug pricing
Roche
Herceptin
Amgen
Kanjinti
Viatris
Ogivri
Pfizer
Trazimera
Teva Pharmaceutical
Herzuma
Organon
Ontruzant
FTC’s Challenge to Amgen-Horizon Merger Sparks Industry Attention
BioSpace
Wed, 06/7/23 - 11:15 am
Amgen
Horizon Therapeutics
FTC
M&A
Amgen's Horizon buyout delayed again, pushing closure possibly to December
Fierce Pharma
Mon, 06/5/23 - 10:21 am
Amgen
Horizon Therapeutics
FTC
M&A
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »